- Home
- GXAI vs ADXN Comparison
GXAI vs ADXN Comparison
Compare GXAI & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | ADXN |
|---|---|---|
| Founded | 2021 | 2002 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GXAI | ADXN |
|---|---|---|
| Price | $1.07 | $8.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 88.1K | 7.9K |
| Earning Date | 11-13-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $694,278.00 | $198,824.00 |
| Revenue This Year | N/A | $86.57 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23205.74 | N/A |
| 52 Week Low | $1.00 | $6.51 |
| 52 Week High | $4.41 | $12.05 |
Technical Indicators
Market Signals| Indicator | GXAI | ADXN |
|---|---|---|
| Relative Strength Index (RSI) | 33.85 | 50.72 |
| Support Level | $1.07 | $7.01 |
| Resistance Level | $1.30 | $8.10 |
| Average True Range (ATR) | 0.07 | 0.42 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 4.00 | 65.15 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.